Life Saving Drugs Program – Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) – Guidelines

These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for infantile onset lysosomal acid lipase deficiency (LAL-D) under the Life Saving Drugs Program.

Downloads

Life Saving Drugs Program – Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) – Guidelines

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Date last updated:
Publication type:
Guideline
Audience:
Health sector
Language:
English
Description:

These guidelines include:

  • General information about the Life Saving Drugs Program (LSDP)
  • Treatment of infantile-onset LAL-D through the LSDP
  • Drugs currently available for the treatment of infantile-onset LAL-D through the LSDP
  • Treatment
  • Dosage
  • General, initial and ongoing eligibility requirements
  • LSDP funding conditions
  • Exclusion criteria.

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.